May 22, 2026 | Blog

In modern pharmaceutical manufacturing and biotech manufacturing, timelines often break down at the handoff points between development and manufacturing, between manufacturing and QC, and between operations and third-party logistics partners. Every transfer introduces risk: mismatched documentation, temperature excursions, delays, or missing chain of custody details. As sterile injectable and biologic programs accelerate, clients increasingly require integrated supply chain partners that reduce these handoffs.

 

BioTechnique®, a full service CRDMO, is designed to eliminate these friction points. Its model integrates manufacturing, QC testing, warehousing, digital inventory management, and GDP aligned shipping and freight inside one controlled quality ecosystem—helping teams move faster with fewer points of failure.

 

Why CRDMO + 3PL Integration Matters

Traditional outsourcing often divides responsibilities across many vendors: a fill finish partner, a testing lab, a warehouse, and a separate logistics provider. The result is slower timelines and inconsistent documentation. BioTechnique’s CRDMO model streamlines this by combining critical functions in one platform.

 

BioTechnique’s integrated approach can connect:

• Sterile manufacturing and fill finish workflows
• Onsite QC testing and laboratory support
• 3PL warehousing with validated multitemperature storage (ambient 15–25°C, 2–8°C, −20°C, −80°C, and cryogenic −190°C)
• Realtime digital inventory visibility and recordkeeping
• GDP aligned shipping and freight with real time tracking and documented chain of custody
• Quality systems and documentation via ACE® cloud eQMS

 

Reducing Handoffs = Reducing Errors

External handoffs can create documentation mismatches, labeling delays, temperature excursions during transfers, and slower investigations when data is spread across systems. By keeping manufacturing, QC, warehousing, and logistics inside one quality ecosystem, BioTechnique helps clients maintain a single chain of accountability and reduces time lost to coordination.

 

Direct Receive + Ship: Fewer Vendors to Manage

BioTechnique can receive materials from suppliers and ship directly to and from end customers, reducing the coordination burden for supply chain teams. Integrating this with temperature qualified storage and compliant shipping helps maintain cold chain integrity and strengthens chain of custody across the lifecycle.

 

Integrated QC: A Major Advantage Over Standard 3PL Providers

Unlike warehouse only 3PL providers, BioTechnique offers value added material services such as onsite QC testing, material labeling, and compliant material destruction. These services reduce supply chain handoffs and support efficient material lifecycle management under controlled conditions.

 

A CRDMO model that integrates manufacturing and 3PL can shorten timelines by reducing vendor transfers and keeping documentation consistent. BioTechnique’s integrated platform streamlines the transition from manufacturing to storage and distribution.

 

About BioTechnique®

BioTechnique, a division of PSC Biotech Corporation, is a full-service Contract Research, Development, and Manufacturing Organization (CRDMO) specializing in cytotoxic and therapeutic sterile injectable fill-finish services. BioTechnique provides comprehensive support from investigation and clinical stages through commercialization, batch sizes both large and small.

 

BioTechnique operates a state-of-the-art facility designed to handle a diverse range of pharmaceutical products, including cytotoxic and highly potent compounds, therapeutics, antibody-drug conjugates (ADCs), monoclonal antibodies, suspensions, and vaccines. Supported by an environmentally controlled warehouse and adaptable manufacturing systems, BioTechnique is committed to delivering high-quality fill finish solutions.

 

Explore more of BioTechnique’s capabilities at https://biotechnique.com/

Follow BioTechnique on LinkedIn for more updates and resources: https://www.linkedin.com/company/biotechnique/